Implants for the treatment of dopamine associated states
AssigneesNuPathe, Inc., The Trustees of the University of Pennsylvania
InventorsTerri B. Sebree, Steven J. Siegel
Life of this patent
Estimating the term…
Abstract
Biodegradable implants comprising dopamine modulating compounds are described.
Claims34
A method for treating a subject for a dopamine associated state, comprising administering to said subject a biodegradable implant, wherein said implant comprises a homogenous mixture of at least one biodegradable polymer and an effective amount of a dopamine modulating compound, such that said subject is treated for said dopamine associated state, wherein said implant comprises a biodegradable hydrophobic coating disposed about the homogenous mixture, such that the drug is delivered gradually rather than with an initial burst and is effective to maintain an effective plasma level for at least a desired delivery period.
A method for treating a subject for Parkinson's disease, comprising administering to said subject a biodegradable implant, wherein said implant comprises a homogenous mixture of at least one biodegradable polymer and an effective amount of ropinirole, such that said subject is treated for Parkinson's disease, wherein said implant comprises a biodegradable hydrophobic coating disposed about the homogenous mixture, and wherein said implant releases ropinirole after implantation such that a plasma level of between about 1 ng/mL and about 40 ng/mL in said subject is maintained for at least three months.
A method for treating a subject for a dopamine associated state, comprising administering to said subject a biodegradable implant, wherein said implant comprises a homogenous mixture of at least one biodegradable polymer and an effective amount of a dopamine modulating compound, such that said subject is treated for said dopamine associated state, wherein said implant comprises a biodegradable hydrophobic coating disposed about the homogenous mixture, wherein said dopamine modulating compound is of formula (I):
- wherein:
- R is amino, alkylamino, di-alkylamino, alkenylamino, dialkenylamino, N-alkyl-N-alkenylamino, benzylamino, dibenzylamino, arylalkylamino, or diarylalkylamino;
- R1, R2 and R3 are each independently hydrogen or alkyl;
- and
- n is 1, 2, or 3, and pharmaceutically acceptable salts thereof, and wherein said effective amount results in a plasma level of said dopamine modulating compound between about 1 ng/mL and about 40 ng/mL in said subject for at least one week.
Dependencies are inferred from the claim text.